Becker's Healthcare September 19, 2024
Alexandra Murphy

BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18.

The company plans to offer 7.5 million shares priced between $17 and $19 each,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
New migraine drugs less effective than previous generation of triptan meds: BMJ study
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
Is Wegovy Shrinking Bariatric Surgery, Too?
Can the Fed’s rate cut change biotech’s ‘new normal’?
Novo Nordisk and NanoVation Inked $600M+ Genetic Medicine Deal

Share This Article